CVI Holdings’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

CVI Holdings’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,854	Closed	-$1.25K	–	419
2023 Q1	$1.25K	Sell	30,854 -43,223	-58%	-$2.98K	﹤0.01%	394
2022 Q4	$3.78K	Sell	74,077 -34,244	-32%	-$1.22K	﹤0.01%	469
2022 Q3	$3K	Sell	108,321 -7,664	-7%	-$485	﹤0.01%	783
2022 Q2	$3K	Hold	115,985	–	–	﹤0.01%	894
2022 Q1	$20K	Sell	115,985 -2,348	-2%	-$952	﹤0.01%	782
2021 Q4	$69K	Hold	118,333	–	–	﹤0.01%	716
2021 Q3	$85K	Hold	118,333	–	–	0.01%	666
2021 Q2	$123K	Hold	118,333	–	–	0.01%	559
2021 Q1	$108K	Buy	+118,333	New	+$192K	0.01%	478

CVI Holdings's EUCRW Position: Q2 2023 in Review

CVI Holdings sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 30,854 shares — an estimated $1.25K sold.

CVI Holdings first reported a position in EUCRW in Q1 2021 and held it in 9 quarters. The position peaked at $123K in Q2 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

CVI Holdings reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
CVI Holdings sold 30,854 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $1.25K.
CVI Holdings first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 9 quarters.
CVI Holdings's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $123K in Q2 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on CVI Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.